Dabrafenib vs. Combination Therapy in Thyroid Cancer Trial w/ Dr. Busaidy

We are honored to have Dr. Naifa Busaidy present "Dabrafenib vs. Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized Phase 2 Open-Label Multicenter Trial." Dr. Frank Worden joins as the featured expert discussant. 0:00 Webinar 2:21 Dr. Busaidy presents 25:57 Dr. Worden presents 42:27 Discussion with Q&A ** Check out our other programs! ** The THANC Guide https://thancguide.org/ TIRO: Thyroid Int'l Recommendations Online https://tiro.expert/ ** Follow us on Twitter! ** @thancfoundation - https://shorturl.at/puwS0 THANC on FB - https://shorturl.at/svNY4